Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

NCT07748364 is registered in ClinicalTrials.gov with Joshua Brody as lead sponsor.

NCT NCT07748364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07748364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
Lead sponsor
Joshua Brody
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
July 31, 2027
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory diffuse large b-cell lymphoma, relapsed/refractory mantle cell lymphoma